3/8
11:37 pm
arwr
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares [Yahoo! Finance]
High
Report
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares [Yahoo! Finance]
3/8
07:33 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy [Yahoo! Finance]
3/8
07:30 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
3/6
07:38 am
arwr
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value [Yahoo! Finance]
Low
Report
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value [Yahoo! Finance]
3/4
07:30 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Medium
Report
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
2/8
03:36 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
2/8
08:11 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.
2/8
06:46 am
arwr
Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
2/7
02:46 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Citigroup Inc. from $33.00 to $34.00. They now have a "neutral" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Citigroup Inc. from $33.00 to $34.00. They now have a "neutral" rating on the stock.
2/7
12:34 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
2/7
10:57 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
2/6
04:48 pm
arwr
Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... [Yahoo! Finance]
2/6
04:01 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
Medium
Report
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
2/6
04:22 am
arwr
Global Viral Sensitizers Market Research Report 2023-2035: Development of Gene Therapy Breakthroughs and Surging Demand for Vaccines Emerge as Key Drivers [Yahoo! Finance]
Medium
Report
Global Viral Sensitizers Market Research Report 2023-2035: Development of Gene Therapy Breakthroughs and Surging Demand for Vaccines Emerge as Key Drivers [Yahoo! Finance]
1/31
08:46 am
arwr
Mirus Bio Receives ISO 13485:2016 Certification [Yahoo! Finance]
Low
Report
Mirus Bio Receives ISO 13485:2016 Certification [Yahoo! Finance]
1/22
04:11 pm
arwr
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results [Yahoo! Finance]
1/22
04:01 pm
arwr
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
Medium
Report
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
1/22
08:19 am
arwr
Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years [Yahoo! Finance]
Low
Report
Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years [Yahoo! Finance]
1/18
05:11 pm
arwr
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk [Yahoo! Finance]
Low
Report
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk [Yahoo! Finance]
1/16
10:15 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $50.00 price target on the stock.
1/5
05:09 pm
arwr
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million [Yahoo! Finance]
High
Report
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million [Yahoo! Finance]
1/5
05:00 pm
arwr
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
High
Report
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
1/3
07:04 am
arwr
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock [Yahoo! Finance]
1/3
07:00 am
arwr
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
Medium
Report
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
1/2
11:15 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Bank of America Co. from $29.00 to $37.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target raised by analysts at Bank of America Co. from $29.00 to $37.00. They now have a "buy" rating on the stock.